The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The last time I spoke about Replimune Group, Inc. (REPL), it was with a Seeking Alpha article entitled "Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating." With respect to this ...
Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. RP1 demonstrates real antitumor activity and durable ...
Replimune Group Inc is listed on the CBOE trading with ticker code REPL.US. It has a market capitalisation of $1.15b, with approximately 84.03m shares in issue. Over the last year, Replimune Group Inc ...
Hosted on MSN
Why is REPL stock soaring 127% after hours today?
・The panel voted 10-3 that the results from a key clinical study of the company’s therapy, known as RP1, were both reliable and clinically meaningful for certain patients with advanced melanoma. ・RP1 ...
In 1974, the U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program funded the Fred Hutch to establish the Cancer Surveillance System (CSS). Our mission is to ...
Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Michael Boyle is an experienced financial professional with more ...
SAN DIEGO, July 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Replimune Group, Inc. (NASDAQ: REPL) or certain of its executive officers violated state or federal ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results